活检证实的脂肪性肝病亚型的临床结局与纤维化模式:多中心前瞻性队列研究
该多中心前瞻性队列纳入2551例活检证实的SLD或非SLD对照,随访中位43.8个月。与非SLD相比,MetALD和ALD的全因死亡及肝脏相关事件风险显著升高;AI定量分析显示MetALD和ALD在门管区及2区胶原密度高于MASLD,提示不同纤维化进展途径。
要点
- MetALD和ALD较非SLD的全因死亡及肝脏相关事件风险显著增加。
- 晚期纤维化(≥F3)亚组中,ALD的死亡和肝脏相关事件风险高于MASLD。
- AI分析显示MetALD和ALD的门管区及2区胶原密度显著高于MASLD。
核心结论
- MetALD和ALD与非SLD相比独立关联全因死亡和肝脏相关事件风险显著增加。
- AI识别的区域特异性胶原模式提示MetALD和ALD存在独特纤维化进展途径,支持定制化风险分层和管理策略。
研究设计与样本
- 多中心前瞻性队列研究,2010至2023年纳入2551例活检证实的SLD或非SLD对照。
- 采用Fine-Gray模型评估全因死亡、肝脏相关事件、心血管疾病和肝外恶性肿瘤风险。
- 对88例肝活检(28例MASLD、30例MetALD、30例ALD)行基于二次谐波成像的AI定量纤维化分析。
主要发现
- 中位随访43.8个月期间发生166例死亡和162例肝脏相关事件。
- 与非SLD相比,MetALD全因死亡ASHR为3.05(95%CI 1.08-8.58),ALD为5.80(95%CI 2.26-14.87)。
- 与非SLD相比,MetALD肝脏相关事件ASHR为6.13(95%CI 1.33-28.20),ALD为10.96(95%CI 2.55-47.14)。
- 晚期纤维化(≥F3)亚组中,ALD的死亡和肝脏相关事件风险高于MASLD。
- AI分析显示MetALD和ALD在门管区和2区的胶原密度显著高于MASLD,尽管常规纤维化分期相当。
临床怎么用
- 对MetALD和ALD患者应重视全因死亡和肝脏相关事件的风险评估与监测。
- 晚期纤维化(≥F3)的ALD患者可能需要更密切的随访和管理。
- AI定量胶原分布分析可能辅助识别常规分期之外的纤维化进展差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clinical outcomes and histologic characteristics of biopsy-proven steatotic liver disease (SLD) subtypes remain understudied. We investigated clinical outcomes and fibrosis patterns in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD). METHODS: This multicenter prospective cohort study enrolled 2551 individuals with biopsy-proven SLD or non-SLD controls between 2010 and 2023. Risks of all-cause mortality, liver-related events (LREs), cardiovascular disease, and extrahepatic malignancies were assessed using Fine-Gray models. Artificial intelligence (AI)-based quantitative fibrosis analysis using second harmonic generation imaging was performed on 88 liver biopsies (28 MASLD, 30 MetALD, and 30 ALD) to assess zone-specific collagen distribution patterns. RESULTS: During a median follow-up of 43.8 months, 166 deaths and 162 LREs occurred. Compared with non-SLD, MetALD (adjusted subdistribution hazard ratio [ASHR], 3.05; 95% confidence interval [CI], 1.08-8.58) and ALD (ASHR, 5.80; 95% CI, 2.26-14.87) demonstrated substantially increased all-cause mortality risk. MetALD (ASHR, 6.13; 95% CI, 1.33-28.20) and ALD (ASHR, 10.96; 95% CI, 2.55-47.14) also exhibited elevated LRE risk. In the advanced fibrosis (≥F3) subgroup, ALD demonstrated higher mortality and LRE risks than MASLD. AI-based analysis revealed that MetALD and ALD exhibited significantly higher collagen density in periportal and zone 2 regions compared with MASLD, despite comparable conventional fibrosis stages. CONCLUSIONS: MetALD and ALD are independently associated with substantially increased all-cause mortality and LRE risks compared with non-SLD. Distinct zone-specific collagen patterns identified by AI analysis suggest unique fibrotic progression pathways in MetALD and ALD, supporting the need for tailored risk stratification and targeted management strategies.
引用
- Kim GA, Jang H, Kim MY, et al. Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes. Gastroenterology. 2026. PMID: 41620039. doi:10.1053/j.gastro.2026.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。